Testing effectiveness (Phase 2)Active Not RecruitingNCT02858921
What this trial is testing
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Who this might be right for
Melanoma
Melanoma Institute Australia 60